logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9884832 B1

PDFFull Text
Date of Patent:
Feb. 06, 2018

Filed:

Dec. 06, 2012

Inhibitors targeting drug-resistant influenza a

Applicant:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

William F. DeGrado, San Francisco, CA (US);

Jizhou Wang, Eagleville, PA (US);

Jun Wang, Philadelphia, PA (US);

Hyunil Jo, Bryn Mawr, PA (US);

Belgin Canturk, Burlington, NJ (US);

Assignee:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Attorney:

Baker & Hostetler LLP

Primary Examiner:

Robert Havlin

Int. Cl.
CPC ...
C07D 413/04 (2006.01); A61K 31/422 (2006.01); C07D 271/06 (2006.01); C07D 207/335 (2006.01); A61K 31/417 (2006.01); A61K 45/06 (2006.01); C07C 215/50 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/15 (2006.01); C07C 211/38 (2006.01); C07C 271/28 (2006.01); A61K 31/27 (2006.01); C07C 255/58 (2006.01); A61K 31/26 (2006.01); C07D 257/04 (2006.01); A61K 31/41 (2006.01); A61K 31/4245 (2006.01); C07D 213/38 (2006.01); A61K 31/4402 (2006.01); C07D 233/88 (2006.01); A61K 31/505 (2006.01); C07D 261/08 (2006.01); A61K 31/5377 (2006.01); C07C 211/27 (2006.01); C07C 211/49 (2006.01); C07C 217/58 (2006.01); C07C 219/28 (2006.01); C07C 233/43 (2006.01); C07C 235/20 (2006.01); C07C 237/30 (2006.01); C07C 255/24 (2006.01); C07C 317/32 (2006.01); C07C 323/32 (2006.01);
U.S. Cl.
CPC ...
C07D 271/06 (2013.01); A61K 31/137 (2013.01); A61K 31/15 (2013.01); A61K 31/155 (2013.01); A61K 31/26 (2013.01); A61K 31/27 (2013.01); A61K 31/41 (2013.01); A61K 31/417 (2013.01); A61K 31/4245 (2013.01); A61K 31/4402 (2013.01); A61K 31/505 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07C 211/27 (2013.01); C07C 211/38 (2013.01); C07C 211/49 (2013.01); C07C 215/50 (2013.01); C07C 217/58 (2013.01); C07C 219/28 (2013.01); C07C 233/43 (2013.01); C07C 235/20 (2013.01); C07C 237/30 (2013.01); C07C 255/24 (2013.01); C07C 255/58 (2013.01); C07C 271/28 (2013.01); C07C 317/32 (2013.01); C07C 323/32 (2013.01); C07D 207/335 (2013.01); C07D 213/38 (2013.01); C07D 233/88 (2013.01); C07D 257/04 (2013.01); C07D 261/08 (2013.01); A61K 31/422 (2013.01); C07C 2601/02 (2017.05); C07C 2603/74 (2017.05); C07D 413/04 (2013.01);
Abstract

Provided are compounds according to formula (Ia) or (Ib) as described herein, that are capable of modulating the activity of influenza viruses (e.g., influenza A virus), for example, via interaction with the M2 transmembrane protein, and other similar viroporins. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds according to according to formulas (Ia') or (Ib), as described herein.

Find Patent Forward Citations

Loading…